Medi Mold (AMTZ) enters into a strategic partnership with OIC International with an investment outlay of over INR 100+ crore to establish India’s first 3D-printed orthopaedic implants manufacturing facility in Vizag

Wodehouse Capital leads transaction advisory, supporting OIC’s strategic entry into India

Medi-Mold, a leading manufacturer of medical-grade molds and precision tooling based within the Andhra Pradesh MedTech Zone (AMTZ), has entered into a strategic partnership with OIC International (USA) and AddUp (France) to establish a state-of-the-art 3D printed orthopaedic implant manufacturing facility in Vizag, India.

The memorandum of understanding for this strategic collaboration was signed in New Delhi in the presence of Mr. Ajay Sood, Principal scientific adviser to the Government of India (PMO Office, New Delhi).

The partnership brings together US-based OIC’s FDA-approved implant technology, French additive manufacturing systems, and India’s largest MedTech ecosystem (AMTZ). A dedicated manufacturing line will be set up within AMTZ to produce 3D-printed orthopaedic implants across trauma, spine, hip, and other segments.

Shri Shetty, Co-Founder & CEO, OIC International said, “This partnership strengthens our commitment to India and enables us to bring world-class, FDA-approved, 3D printed orthopaedic implants to one of the fastest-growing markets globally.”

As part of the transaction, Medi-Mold has agreed to an investment outlay of INR over 100 crores towards OIC International’s setup, India entry, manufacturing, and expansion plans. The capital will be deployed to set up and scale the 3D printed implants facility and localize production, thereb y reducing India’s reliance on imports. It will also support the transfer of proprietary technology, patents, and manufacturing SOPs, and the development of a specialized workforce for advanced MedTech manufacturing.

The facility will leverage AMTZ’s advanced testing labs, machining centres, and regulatory infrastructure to produce high-quality implants at globally competitive costs. This entire initiative is well supported by Dr. Jitendra Sharma, AMTZ.

Dr. Teja, Chief Executive Officer from Medi-Mold added, “AMTZ and Medi Mold are proud to host this technologically advanced facility, aligning with India’s vision of becoming a global MedTech manufacturing hub.”

Wodehouse Capital Advisors acted as the exclusive financial and India market entry advisor to OIC for this transaction. The firm supported the evaluation of suitable partners, the structuring of the commercial arrangement, and the overall approach for OIC’s expansion into India. This marks Wodehouse Capital’s fifth healthcare transaction in the last 12 months, reflecting its continued work across the healthcare sector in segments such as medical devices, diagnostics, and single-specialty healthcare services.

Sraboni Haralalka, Executive Director, Wodehouse Capital Advisors said, “We are delighted to have advised on this marquee cross-border transaction. This collaboration sets the stage for India to emerge as a global center for advanced orthopaedic implant manufacturing.”

About the Partners

OIC International (USA):
 A global healthcare company specialising in FDA-approved, 3D printed orthopaedic implants supported by 40+ approvals and multiple patents.

Medi-Mold / AMTZ (India):
A leading precision tooling manufacturer within the Andhra Pradesh MedTech Zone — India’s largest integrated MedTech manufacturing ecosystem. This entire initiative is well supported by Dr Jitendra Sharma.

AddUp (France):
A subsidiary of the billion-dollar Fives Group and a global leader in industrial metal additive manufacturing technologies.

Wodehouse Capital Advisors (India):

Wodehouse Capital Advisors is a mid-market focused global investment bank, driving high-impact M&A, fund-raising, strategic partnerships, and India market entry mandates. With a proven track record of 50+ successful transactions across Healthcare, Industrials, Consumer and Business Services. WCA combine deep sector expertise with large-scale investor access to deliver high-impact outcomes.